Vireo Growth (VREOF) CEO details RSU vesting, share grants and withholding
Rhea-AI Filing Summary
Vireo Growth Inc. chief executive officer and director John Mazarakis reported multiple equity compensation events involving subordinate voting shares. On November 13, 2025 and December 17, 2025, he acquired a total of 10,937,736 subordinate voting shares, primarily from restricted stock units (RSUs) that vested and settled immediately. After these transactions, he held 14,137,736 subordinate voting shares directly before tax withholdings.
On December 29, 2025, RSUs that had vested on November 13 and December 17 were settled, and 801,849 and 3,502,150 subordinate voting shares, respectively, were withheld to cover taxes. The filing also corrects a prior RSU vesting schedule, confirming 5,700,000 RSUs vest on December 17, 2025, with additional tranches of 6,650,000 RSUs vesting on or after December 17, 2026 and December 17, 2027, subject to 30-day VWAP price hurdles and continued service.
Positive
- None.
Negative
- None.
FAQ
What insider transactions did Vireo Growth Inc. (VREOF) report for its CEO?
The chief executive officer, John Mazarakis, reported acquiring subordinate voting shares through restricted stock unit (RSU) vesting on November 13, 2025 and December 17, 2025. These transactions increased his direct holdings to 14,137,736 subordinate voting shares before subsequent tax withholdings on December 29, 2025.
How many Vireo Growth (VREOF) shares were withheld for taxes in this Form 4?
On December 29, 2025, 801,849 subordinate voting shares related to RSUs that vested on November 13, 2025, and 3,502,150 subordinate voting shares related to RSUs that vested on December 17, 2025, were withheld to satisfy tax obligations.
What RSU vesting schedule did Vireo Growth (VREOF) correct for its CEO?
The filing corrects an earlier vesting schedule, stating that 5,700,000 RSUs vest on December 17, 2025; 6,650,000 RSUs vest on or after December 17, 2026 once the subordinate voting shares reach a 30-day VWAP above US$0.85; and another 6,650,000 RSUs vest on or after December 17, 2027 once the 30-day VWAP exceeds US$1.05, subject to Mr. Mazarakis remaining a service provider on each vesting date.
What is the relationship of the reporting person to Vireo Growth Inc. (VREOF)?
The reporting person, John Mazarakis, is both a director and the chief executive officer of Vireo Growth Inc., as indicated by the relationship section of the filing.
How many subordinate voting shares does the Vireo Growth (VREOF) CEO own after the reported transactions?
Following the reported non-derivative share transactions, the CEO beneficially owned 9,833,737 subordinate voting shares directly as of the last reported transaction on December 29, 2025.
What type of derivative security is involved in this Vireo Growth (VREOF) Form 4?
The derivative securities are restricted stock units (RSUs). Each RSU represents a contingent right to receive one subordinate voting share, with 5,700,000 RSUs converted into 5,700,000 subordinate voting shares reported in the derivative table.